Sanofi has agreed to buy UK start-up Vicebio, which was formed to produce improved, more potent shots that are simpler to manufacture, for $1.6bn.

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a ...